CLNN News and Press, Clene Inc. From 09/05/25

2025-09-05 16:37:25 ET More on Clene Seeking Alpha’s Quant Rating on Clene Historical earnings data for Clene Financial information for Clene Read the full article on Seeking Alpha For further details see: Clene files to sell 491,496 shares...

2025-09-04 11:39:36 ET Clene (NASDAQ: CLNN) , through its wholly owned subsidiary Clene Nanomedicine Inc., announced new preclinical data demonstrating that CNM-Au8(R) improved mitochondrial function, reduced inflammation, and restored cellular metabolism in a novel dopaminergic neuron ...

2025-09-04 10:05:00 ET According to new research published in the journal Cell , targeting the SOX6 protein could open a new way to repair myelin in individuals afflicted by multiple sclerosis. According to the researchers, this SOX6 protein regulates the maturation of cells referre...

Novel human preclinical neuronal model for Parkinson’s disease demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression in both familial and sporadic Parkinson’s disease ...

2025-09-02 09:25:00 ET Clene (NASDAQ: CLNN) announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference and host one-on-one investor meetings. To view the full press release, visit https://ibn.fm/d4eRn About Clene Inc. Clene...

SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative ...

2025-08-29 14:55:30 ET Clene (NASDAQ: CLNN) , together with its wholly owned subsidiary, Clene Nanomedicine Inc., is advancing its lead candidate CNM-Au8®, a unique and needed oral treatment for amyotrophic lateral sclerosis (“ALS”), toward a potential FDA accelerated...

2025-08-14 11:11:27 ET More on Clene Seeking Alpha’s Quant Rating on Clene Historical earnings data for Clene Financial information for Clene Read the full article on Seeking Alpha For further details see: Clene GAAP EPS of -$0.78 misses by...

Following constructive FDA feedback on its proposed statistical analysis plan, Clene plans to analyze the neurofilament light data from its large NIH-sponsored Early Access Protocol early in the fourth quarter of 2025 A second Type C meeting has been scheduled with the FDA in the third qu...

Western Uranium & Vanadium Corp (WSTRF) is expected to report for Q2 2025 IceCure Medical Ltd. (ICCM) is expected to report $-0.06 for Q2 2025 TFF Pharmaceuticals Inc - Ordinary Shares (TFFP) is expected to report for quarter end 2025-06-30 Scientific Industries, Inc. (SCND) is ex...